Harmony prenatal test utilizes company’s proprietary technology to perform a directed, non-invasive analysis of cell-free DNA (cfDNA)in maternal blood.

Ariosa said its proprietary biochemistry and algorithm platforms work together to analyze patient samples in order to provide individualized risk scores.

Ariosa Diagnostics chief executive officer Ken Song said the Harmony prenatal test supports findings from the company’s previous studies recently published in the American Journal of Obstetrics and Gynecology and Prenatal Diagnosis demonstrating accurate fetal trisomy detection.